|
08:30 |
Registration and Breakfast |
|
Outsourcing Product Development |
|
09:30 |
Keynote Presentation
Working with Biotech and Academia to Facilitate Drug Discovery in Big Pharma
Raymond Hill, Former Executive Director, Licensing & External Research Europe, Merck, Sharpe & Dohme, Imperial College London
Much of the innovation needed to discover new drugs is happening in academic labs or in biotech companies so that it is vital for big Pharma to have access to this resource. However, there are cultural differences between big companies and their putative partners that need to be overcome if the full potential of these interactions is to be realised. |
|
10:30 |
Coffee and Networking in the Exhibition Hall |
|
11:15 |
Challenges for Medicinal Chemists in Successful and Effective Collaborations & Partnerships in Drug Discovery
Roderick Porter, Business Development Director, NiKem Research
Different client needs, require different flexible collaboration models for chemistry CRO organisations. These models will be discussed and exemplified with a case history |
|
11:45 |
New Approaches for De-Risking and Accelerating Your Pipeline
Katherine Tsaioun, CSO, Apredica
Extending the drug discovery programs' runways is a top concern for most pharmaceutical industry executives. We'll present new approaches and case studies describing ADME-Tox strategies that de-risk drug discovery programs. |
|
12:30 |
Lunch and Networking in the Exhibition Hall |
|
13:30 |
Selecting the Right Partner/Strategy for Outsourcing
Lena Martensson, Director & Head of Strategic Planning and Business Development, AstraZeneca
The strategic driver for outsourcing is very much different in various Pharma companies and depends on what stage that the company itself is in. These drivers will be discussed; various models to use and some examples from AstraZeneca will be described. |
|
14:00 |
Clinical Trial Outsourcing: Value of Accredited Training and Center Assessment
Heinrich Klech, CEO & Executive Vice President, Vienna School of Clinical Research
The key to foster medical development and innovation is to invest in people's skills
How to enhance the credibility of obtained data
How to cope with increasing complexity in clinical trials
Value of academic accreditation
Need for standardized education curricula for CT staff |
|
14:30 |
Legal and Regulatory Issues when Outsourcing Clinical Trials
Gerry Kamstra, Partner, Bird & Bird
The presentation will review issues arising in the review of the Clinical Trials Directive 2001/20/EC by the European Commission and the EMEA and their implications with regard to clinical trial contracts. |
|
15:15 |
Coffee and Networking |
|
16:15 |
Lead Structure Optimization of Kinase Inhibitors with Unique Profile
Thierry Langer, CEO, Prestwick Chemical
Structure-based ligand design supported by large scale in silico ligand profiling merged with traditional medicinal chemistry and first class biological testing yields to interesting compounds with unique kinase binding pattern. |
|
16:45 |
Close of Conference |